The partnership aims to enable a more complete telehealth solution focused on the unique needs of the complex, chronic, co-morbid patient population.
The system creates 3D electroanatomic maps of the heart by collecting ECG signals from the chest, and combining these signals with data from a CT scan.
New iPro2 myLog app collects data from CGMs and Fitbit activity trackers to provides meaningful insights on how exercise impacts glucose levels.
Under the deal, Medtronic will be a reseller and distributor of Canary Health's programs, including its CDC-recognized Diabetes Prevention Program (DPP).
MyCareLink Smart Monitor is comprised of a handheld portable device reader and the MyCareLink Smart mobile app, that works on iOS and Android devices.
The two giants are looking to accelerate the development of digital health solutions for patients who could benefit from neuromodulation therapy.
The company is also announcing the U.S. product availability allowing patients to use own mobile devices to transmit data from their pacemakers to physicians.
Working in tandem with a companion app, the device enables people with diabetes to conveniently view their insulin pump and CGM information on a smartphone.
The two giants will combine their respective strengths to develop a range of future solutions that will make it easier for diabetics to manage their condition.
Under the deal, Medtronic will be providing telehealth devices to LHC Group's existing care transitions program T3, to prevent avoidable readmissions.
12Page 1 of 2